title: Is there really misuse and abuse of dabigatran?
authors.affiliation: Department of Medicine, McMaster University, Hamilton, Ontario, Canada. eikelbj@mcmaster.ca
authors.forename: John W
authors.initials: JW
authors.lastname: Eikelboom
authors.forename: Graeme J
authors.initials: GJ
authors.lastname: Hankey
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D000991:Antithrombins / Q000008:administration & dosage* / Q000009:adverse effects* / Q000191:economics; D001562:Benzimidazoles / Q000008:administration & dosage* / Q000009:adverse effects* / Q000191:economics; D000069604:Dabigatran; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D009203:Myocardial Infarction / Q000453:epidemiology; D018579:Patient Selection; D011358:Product Surveillance, Postmarketing; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D020521:Stroke / Q000517:prevention & control; D014859:Warfarin / Q000627:therapeutic use; D015091:beta-Alanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000191:economics
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D001562:Benzimidazoles; D015091:beta-Alanine; D014859:Warfarin; D000069604:Dabigatran